Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer
Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer
复制标题
DOI：
10.1016/j.canlet.2005.12.016
复制
发表时间：
2006-12-08
期刊：
影响因子：
9.7
通讯作者：
Kong, Gu
中科院分区：
文献类型：
--
作者：
Jang, Ki-Seok;Han, Hong Xiu;Kong, Gu
本研究的目的是探讨DNA结合抑制剂（Id-1）过表达在人乳腺癌中的可能作用。我们采用免疫组化方法检测了263例人乳腺癌、15例原位病变和248例浸润性肿瘤中Id-1的表达，探讨其表达与各种临床病理因素的关系。Id-1在浸润性导管癌中的表达明显高于原位导管癌和其他浸润性癌亚型（P分别为0.029和0.006）。我们还通过测量微血管密度（MVD）检测了Id-1表达与肿瘤血管生成之间的关系。微血管内皮细胞Id-1表达阴性或极弱，Id-1过表达与MVD显著相关（P=0.014）。此外，在er阴性和淋巴结相关的乳腺癌亚组中，Id-1过表达与较高的MVD显著相关（P分别为0.040和0.046）。这些数据表明，Id-1过表达与肿瘤血管生成显著相关，特别是在浸润性乳腺癌的er阴性和淋巴结阳性亚型中。因此，Id-1可能是er阴性和淋巴结阳性乳腺癌的治疗性抗肿瘤靶点分子。2006爱思唯尔爱尔兰有限公司版权所有。
The aim of this study is to investigate the possible role of inhibitor of DNA binding (Id-1) overexpression in human breast cancer. We examined Id-1 expression by immunohistochemistry in 263 human breast cancers, 15 in situ lesions and 248 invasive cancers to investigate the relationship between its expression and various clinicopathological factors. Id-1 expression was significantly higher in invasive ductal carcinoma than in in situ ductal carcinoma or other invasive cancer subtypes (P = 0.029 and 0.006, respectively). We also examined the association between Id-1 expression and tumor angiogenesis by measuring microvessel densities (MVD). Regarding the endothelial cells of microvessels showed negative or very weak Id-1 expression, Id-1 overexpression was found to be significantly related to MVD (P=0.014). Furthermore, Id-1 overexpression was found to be significantly associated with higher MVD in the ER-negative and node-involved subgroups of breast cancer (P = 0.040 and 0.046, respectively). These data indicate that Id-1 overexpression is significantly associated with tumor angiogenesis, especially in the ER-negative and node-positive subtypes of invasive breast cancer. Thus, Id-1 presents a possible therapeutic antitumor target molecule in ER-negative and node-positive breast cancer. (c) 2006 Elsevier Ireland Ltd. All rights reserved.